Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;67(10):1911-1922.
doi: 10.2337/dbi17-0045.

A Global Overview of Precision Medicine in Type 2 Diabetes

Hugo Fitipaldi  1 , Mark I McCarthy  2   3 , Jose C Florez  4   5   6 , Paul W Franks  7   2   8   9
Affiliations

A Global Overview of Precision Medicine in Type 2 Diabetes

Hugo Fitipaldi et al. Diabetes. 2018 Oct.

Abstract

The detailed characterization of human biology and behaviors is now possible at scale owing to innovations in biomarkers, bioimaging, and wearable technologies; "big data" from electronic medical records, health insurance databases, and other platforms becoming increasingly accessible; and rapidly evolving computational power and bioinformatics methods. Collectively, these advances are creating unprecedented opportunities to better understand diabetes and many other complex traits. Identifying hidden structures within these complex data sets and linking these structures to outcome data may yield unique insights into the risk factors and natural history of diabetes, which in turn may help optimize the prevention and management of the disease. This emerging area is broadly termed "precision medicine." In this Perspective, we give an overview of the evidence and barriers to the development and implementation of precision medicine in type 2 diabetes. We also discuss recently presented paradigms through which complex data might enhance our understanding of diabetes and ultimately our ability to tackle the disease more effectively than ever before.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Global precision medicine initiatives of relevance to type 2 diabetes.
Figure 2
Figure 2
The path to precision medicine in type 2 diabetes. HEA, health economic assessment.
See this image and copyright information in PMC

Comment in

  • In This Issue of Diabetes.
    [No authors listed] [No authors listed] Diabetes. 2018 Oct;67(10):1909-1910. doi: 10.2337/db18-ti10. Diabetes. 2018. PMID: 30237158 No abstract available.

References

    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
    1. Knowler WC, Fowler SE, Hamman RF, et al.; Diabetes Prevention Program Research Group . 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686 - PMC - PubMed
    1. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008;371:1783–1789 - PubMed
    1. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–1350 - PubMed
    1. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP) . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297 - PubMed

Publication types